Search results
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig
Guru Focus· 4 days agoThe company, a biotechnology firm specializing in the development of innovative treatments for pulmonary arterial hypertension (PAH), has reported a significant ...
Gossamer Bio reports positive phase 2 trial results for PAH treatment By Investing.com
Investing.com· 3 days agoGossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company, has announced the...
Merck Supports PAH Patients With Unbranded Campaign -- And New Drug
MediaPost· 6 days agoPatients can “Outnumber PAH” by developing a strong support team, advises an unbranded educational campaign launched by Merck against pulmonary arterial hypertension (< ...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 3 days agoRating of 87. But the biotech stock undercut its 50-day line on April 10. Gyre is also a new...
Q1 2024 United Therapeutics Corp Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 4 days agoAs a reminder, this is a best-in-class once-a-day oral treatment for PAH and its Phase III trial endeavors to show long-term morbidity and mortality benefit ...
Bill banning certain driveway, pavement sealants to take effect this July
Virginia Mercury via Yahoo News· 4 days agoAfter attempting to ban the products in previous sessions, the Democratic legislature passed a bill...
United Therapeutics Surpasses Analyst Revenue Forecasts with Str
Guru Focus· 5 days agoThis performance not only demonstrates robust growth but also significantly exceeds the analyst estimates of $623.97 million for the quarter. United Therapeutics, headquartered in Silver Spring ...
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 6 days agoMerck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats...
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
Zacks via Yahoo Finance· 3 days agoAgios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark,...
